Initial experience of Czech MDS Group with 5-azacytidine in patients with high risk myelodysplastic syndromes (IPSS intermediate II and high), acute myeloid leukaemia with less than 30% myeloblasts and chronic myelomonocytic leukaemia II
Authors:
A. Jonášová 1; J. Čermák 2; L. Červinek 3; L. Nováková 2; P. Bělohlávková 4; J. Vondráková 5; O. Černá 6; M. Sýkora 5; N. Seifertová 5; L. Walterová 7; J. Libiger 8; I. Hochová 9; J. Ullrychová 8; P. Rohoň 10; J. Obernauerová 11; M. Schutzova 12; V. Vozobulová 12; H. Poláčková 1; K. Kačmářová 13; J. Mužík 14
Authors‘ workplace:
Všeobecná fakultní nemocnice, 1. LF UK Praha
1; Ústav hematologie a krevní transfuze, Praha
2; Fakultní nemocnice Brno, Masarykova univerzita, Brno
3; Fakultní nemocnice Hradec Králové
4; Nemocnice České Budějovice
5; Fakultní nemocnice Královské Vinohrady, Praha
6; Nemocnice Liberec
7; Nemocnice Ústí nad Labem, Teplice
8; Fakultní nemocnice Motol, Praha
9; Fakultní nemocnice Olomouc
10; Nemocnice Mladá Boleslav
11; Fakultní nemocnice Plzeň
12; Česká MDS skupina
13; Institut biostatistiky a analýz, Masarykova univerzita, Brno
14
Published in:
Transfuze Hematol. dnes,19, 2013, No. 3, p. 125-133.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Introduction.
Therapy of high risk myelodysplastic syndromes (MDS) remains unsatisfactory. The only treatment that alters the natural history of the disease is allogeneic stem-cell transplantation, which can be offered to a limited number of young patients. Modern therapy predominantly focuses on prolonging survival, postponing potential acute myeloid leukaemia (AML) transformation and improving quality of life (QoL). New epigenetic therapy, especially methyltransferase inhibitors, has achieved these goals. Here, we present the experience of the Czech MDS Cooperative Group with 5-azaci-tidine treatment of patients with intermediate II and high risk MDS patients (IPSS), chronic myelomonocytic leukaemia II (CMML II) and AML with less than 30% myeloblasts in the bone marrow.
Patients and results.
Between October 2008 and June 2012, we used azacitidine treatment in 111 patients (66 M, 45 F), median age 68 years (range 48–85) with the diagnosis: 44 RAEB II, 13 RAEB I, 9 CMML II, 6 RCMD, 28 AML < 30% MB, 7 AML > 30% MB and 4 MDS/MPS. Median follow-up was 8.8 month (range 1–32), median number of cycles of azacitidine was 5 (range 1–28). The most common adverse events included haematological toxicity with neutropenia grade (Gr) 3/4 in 54.9% and thrombocytopenia Gr 3/4 in 70.3%. Non-haematological side effects, mostly only Gr1/2, were gastrointestinal in 21.6% and local reactions and fatigue in 31.5%.
Response.
The overall response rate (ORR) was 42.4% (CR 19.6%, CRi 6.5%, PR 16.3%), stable disease (SD) was achieved in 19.6% and haematological improvement (HI) in 57.4%. After one year, based on Kaplan-Meier estimates, 67.8% of patients were alive and the median overall survival (OS) was 16.4 months. We also analysed several clinical parameters collected at the start of azacitidine treatment as prognostic factors for OS (age, sex, ECOG performance status (PS), transfusion dependency, peripheral blast percentage, neutrophil count, platelet count, bone marrow blast percentage, fibrosis, percenta-ge of erythroid precursors in bone marrow, cytogenetic data, WHO classification, IPSS, primary and secondary aetiology of MDS).
Conclusion.
Our results correlate very well with other published data (AZA 001, CALGB 9221). OS data are comparable with other “real life” studies. It is also important to take into consideration that our group also included very high risk patients (relapsed, refractory to previous treatment, post-transplant patients and AML with more than 30% myeloblasts). Nevertheless, our results are very promising and support the positive effect of azacitidine compared to standard therapy in high risk MDS patients. The analysis performed so far shows that from the aspect of OS, best response correlates with: cytogenetic aberration, peripheral blast count, neutrophil count and ECOG PS.
Key words:
azacytidine, myelodysplastic syndromes, therapy, overall survival, prognostic factors
Sources
1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classifica-tion of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-99.
2. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-49.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-88 (erratum, Blood 1998; 91:1100).
4. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-10.
5. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factor and life expectancy in MDS classified according WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-603.
6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10(3): 223-32.
7. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002; 20(10): 2429-40.
8. Itzykson R, Thépot S, Quesnel B, et al. Groupe Francophone des Myelodysplasies (GFM). Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117(2): 403-11.
9. Curik N, Burda P, Vargova K, et al. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia 2012; 26(8): 1804-11.
10. Schmelz K, Wagner M, Dörken B, Tamm I. 5-Aza-2‘-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer 2005; 114(5): 683-95.
11. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009; 113(6): 1315-25.
12. Figueroa ME, Skrabanek L, Li Y, et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009; 114(16): 3448-58.
13. Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010; 76(3): 218-27.
14. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28(4): 562-9.
15. Raj K, John A, Ho A, et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007; 21(9): 1937- 44.
16. Mufti GJ, Fenaux P, Hellstrom-Lindberg E, et al. Treatment of high risk MDS patients (pts) with -7/del(7q) with azacitidine (AZA) versus conventional care regimens (CCR): effects on overall survival (OS). J Clin Oncol 2008; 26: Abstract 7033.
17. Mufti GJ, Gore SD, Valeria Santini V, et al. Influence of karyotype on overall survival in patients with higher-risk myelodysplastic syndrome treated with azacitidine or a conventional care regimen. Blood 2009; 114: Abstract 1755.
18. Grövdal M, Khan R, Aggerholm A, et al. Maintenance treatment with azacitidine for patients with high risk myelodysplastic syndromes or acute myeloid leukaemia in complete remission after intensive chemotherapy. Br J Haematol 2010; 150(3): 293-302.
19. Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: A study by the Societe Francaise de Greffe de Moelle et de Therapie--Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol 2012; 30: 4533-4540.
20. Quintás-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012; 120: 4840-4845.
21. Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma 2012; 53(1): 110-7.
22. Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011; 117(12): 2697-702.
23. Fenaux P, Bowen D, Gattermann N, et al. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion. Leuk Res 2010; 34(11): 1410-6.
24. Lyons RM, Cosgriff T, Modi S, et al. Results of the initial treatment phase of a study of three alternative dosing schedules of azacitidine (Vidaza®) in patients with myelodysplastic syndromes (MDS). J Clin Oncol 2009; 27(11): 1850-6.
25. Fenaux P, Gattermann N, Seymour JF, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 2010; 149(2): 244-9. (Erratum Br J Haematol 2010 Jun; 149(6): 919).
26. Itzykson R, Thépot S, Beyne-Rauzy O, et al. Groupe Francophone des Myelodysplasies (GFM). Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine? Leuk Res 2012; 36(4): 397-400.
27. Sekeres MA, List AF, Cuthbertson D, et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010; 28(13): 2253-8.
28. Silverman LR. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents. Leuk Res 2009; 33:Suppl 2: S18-21.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2013 Issue 3
Most read in this issue
- Current treatment of myelofibrosis based on risk stratification of patients
- Lymphomas of gastrointestinal tract – clinico-pathological review
- The importance of serum immunoglobulin free light chain assay in AL amyloidosis
- Plasma cell leukaemia